Jagsonpal Pharmaceuticals Ltd

📈 Jagsonpal Pharma Q4 FY26: Revenue Up 10%, Margins Steady

- Q4 FY26 revenue: ₹642 million, up 10% year-over-year

- Full-year revenue: ₹2,872 million, up 7%

- Q4 FY26 EBITDA margin: 16.4% (₹106 million)

- Full-year EBITDA margin: 21.2% (₹609 million)

- Net profit (PAT) for Q4 FY26 surged 31% to ₹88 million

- Full-year PAT grew 19% to ₹446 million

- Cash position strengthened to ₹1,907 million as of March 31, 2026, up ₹451 million

- Board approved ₹40 crore buyback of up to 16 lakh shares at ₹250 per share

- Proposed 200% dividend (including 75% special dividend), totaling ~₹262 million

- Top 10 brands like Indocap, Maintane, and Metadec drove growth, accounting for 58% of revenue

- Growth strategy includes improved sales force productivity, new product launches, and potential acquisitions